CR4056, a first-in-class imidazoline-2 receptor ligand analgesic, in pain from knee osteoarthritis phenotypes: a randomized, placebo-controlled, double-blind, phase iia clinical trial

Autor:	Federica Girolami, Massimo D'Amato, T. Blicharski, Nadia Brambilla, Lucio C. Rovati, N.J. Probert, G. Giacovelli, Cristina Vitalini
Rok vydání:	2018
Předmět:	medicine.medical_specialty business.industry Analgesic Biomedical Engineering Imidazoline receptor Osteoarthritis Ligand (biochemistry) medicine.disease Placebo Gastroenterology Double blind Clinical trial Rheumatology Internal medicine Medicine Orthopedics and Sports Medicine business Receptor
Zdroj:	Osteoarthritis and Cartilage. 26:S308
ISSN:	1063-4584
DOI:	10.1016/j.joca.2018.02.620
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::a754622b40af3226df845d3b65f9643a https://doi.org/10.1016/j.joca.2018.02.620 Zobrazit plný text záznamu Full Text from ScienceDirect